Tirzepatide vs Retatrutide

Structure and mechanism

Tirzepatide is a dual agonist: it activates both the GIP and GLP-1 receptors. Retatrutide goes a step further, adding a third receptor, glucagon, to the same molecule.

Studied outcomes

Both were studied for appetite and metabolic regulation. Tirzepatide's SURMOUNT-1 trial (PMID 35658024, n=2,539) ran 72 weeks. Retatrutide's phase 2 trial (PMID 37366315, n=338) ran 48 weeks and reported larger mean change at the highest dose studied. The two peptides were not tested against each other in the same trial, so the comparison is between separate studies, not a direct one.

How to think about the difference

• Track record. Tirzepatide has a larger studied population and a longer follow-up window.
• Mechanism breadth. Retatrutide's third receptor target is the newer, less-established addition of the two.
• Study design. Neither figure above is a head-to-head result — treat the comparison as two separate datasets, not a controlled contest.

Frequently asked

Is retatrutide "stronger" than tirzepatide? The phase 2 numbers point that direction, but the trials differ in size, duration, and population, so the comparison is indicative, not conclusive. Can research protocols examine both? Some literature covers overlapping incretin-pathway compounds together, but see each compound's own dosing research before drawing conclusions.